Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is currently conducting a Korea Post Marketing Surveillance (PMS) Study of Vizimpro, officially titled ‘A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro®’. The study aims to evaluate the effectiveness and safety of Vizimpro in treating EGFR NSCLC 1L in Korea, ensuring any potential issues are identified post-marketing.
The intervention being tested is Vizimpro, a drug designed for patients with EGFR NSCLC 1L. It is administered as part of routine clinical practice to observe its real-world impact.
The study follows an observational design, specifically a case-only model with a prospective time perspective. This means it observes patients already receiving Vizimpro without altering their treatment regimen, focusing on gathering data over time.
The study began on March 7, 2021, with its most recent update submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
This update may influence Pfizer’s stock performance and investor sentiment, as successful results could enhance Vizimpro’s market position. Competitors in the oncology drug market will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.